Tamibarotene will enter Phase II development as a therapy for APL with potential to treat other cancers.
Innovive Pharmaceuticals acquired exclusive rights from TMRC to develop and commercialize Tamibarotene in Europe. In December 2006, the company gained the North American rights to the drug.
Tamibarotene, a synthetic retinoid drug candidate, will be evaluated in a Phase II pivotal trial in patients with relapsed or refractory acute promyelocytic leukemia (APL) following treatment with all-trans retinoic acid and arsenic trioxide, Innovive reports.
The terms of the agreement between Innovive and TMRC includes an option to license the use of Tamibarotene in other oncology disease areas including multiple myeloma, myelodysplastic syndromes, and solid tumors, except hepatocellular carcinoma.
